SCHEMBL11945306

SCHEMBL11945306

CC(C)COC(=O)N1CCC(Oc2c(N3CCN(S(=O)(=O)Cc4cccc(N)c4)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 4/20 0.36
▸ PPARG P37231 2/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ SCN10A Q9Y5Y9 1/20 0.33
▸ NPBWR1 P48145 1/20 0.32
▸ MCHR1 Q99705 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ CYP2C19 P33261 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ ACACB O00763 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ NCOA2 Q15596 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945282 0.94 GPR119 (0.37) GPR119MAPTPIK3CDSCN9ASCN10A
SCHEMBL11954081 0.94 GPR119 (0.37) GPR119MAPTPIK3CDSCN9ASCN10A
SCHEMBL11945280 0.88 GPR119 (0.37) GPR119MAPTPIK3CDNPBWR1MCHR1
SCHEMBL11944346 0.84 MAPT (0.38) PPARGMAPTTP53CYP2C19MAPK1
SCHEMBL11945358 0.84 MAPT (0.38) PPARGMAPTTP53CYP2C19MAPK1
SCHEMBL11945301 0.82 MAPT (0.34) PPARGMAPTPIK3CDTP53CYP2C19
SCHEMBL11944627 0.79 MAPT (0.39) PPARGMAPTMCHR1CYP2C19MAPK1
SCHEMBL11952555 0.78 POLB (0.41) GPR119PPARGMAPTPIK3CDNPBWR1
SCHEMBL11944266 0.78 POLB (0.41) GPR119PPARGMAPTPIK3CDNPBWR1
SCHEMBL11945305 0.78 TDP1 (0.35) GPR119PPARGMAPTCYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA GPR119 1056/4885PPARG 2194/4885PPARA 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback